Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 9
July 2024
Volume 65, Issue 9
Open Access
ARVO Imaging in the Eye Conference Abstract  |   July 2024
In-vivo retinal imaging of amyloid deposits as biomarker for Alzheimer’s disease
Author Affiliations & Notes
  • Mircea Mujat
    Biomedical Optics Technologies, Physical Sciences Inc, Andover, Massachusetts, United States
  • Ankit Patel
    Biomedical Optics Technologies, Physical Sciences Inc, Andover, Massachusetts, United States
  • John Grimble
    Biomedical Optics Technologies, Physical Sciences Inc, Andover, Massachusetts, United States
  • Nicusor Iftimia
    Biomedical Optics Technologies, Physical Sciences Inc, Andover, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Mircea Mujat, Physical Sciences Inc (E); Ankit Patel, Physical Sciences Inc (E); John Grimble, Physical Sciences Inc (E); Nicusor Iftimia, Physical Sciences Inc (E)
  • Footnotes
    Support  NIH grant 1R43AG074744
Investigative Ophthalmology & Visual Science July 2024, Vol.65, PP0017. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mircea Mujat, Ankit Patel, John Grimble, Nicusor Iftimia; In-vivo retinal imaging of amyloid deposits as biomarker for Alzheimer’s disease. Invest. Ophthalmol. Vis. Sci. 2024;65(9):PP0017.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The purpose of the current study was to evaluate the potential of multispectral high-resolution imaging to identify amyloid β-protein (Aβ) deposits in the retina as a biomarker for neurodegenerative diseases such as Alzheimer’s (AD). We combined simultaneous multi-channels offset and confocal AO-SLO imaging, which provides isotropic images of retinal microstructures free of directionality artifacts, with spectral signature analysis of chemical compounds to identify such biomarkers at cellular-level.

Methods : We have developed a multispectral imaging technique for identifying chemical compounds in vivo in the retina with cellular-level resolution and without the use of contrast agents. Since various retinal structures and cells have different reflectance and absorbance properties, information about cell metabolism and structure can be obtained using spectral imaging. Our method is based on using multiple wavelengths for which Aβ has different attenuation (405 nm, 450 nm, 488 nm, 520 nm and 640 nm). In this way, Aβ can be spectrally differentiated from the surrounding tissue. Our instrument is based on PSI high-resolution retinal imaging platform (MAORI for human and MAOSI for rodent imaging) which has multi-offset capabilities. However, similar to all current AO-SLO systems, our instruments use a single broadband light source (20-50 nm bandwidth) and detect the reflected light with detectors that integrate over the entire spectrum, without spectral differentiation capabilities. To add multispectral capabilities, we replaced the SLO light source with a time-wavelength multiplexed light source to which we synchronized the detection unit.

Results : One confocal and four offset images are acquired for each individual illumination wavelength. Multiple split, phase, phase gradient, sum (ring detection), and standard deviation images are derived for each color and are combined in a manner that highlights spectrally the local variations of attenuation through spectral similarity analysis. The new concept has been demonstrated in a model eye using commercially available Aβ and in vivo on a mouse Alzheimer’s model.

Conclusions : PSI has developed a novel multispectral adaptive optics-based technique for non-invasive detection at cellular-level of Aβ in the retina. This technique may pave a path forward for better understanding of the onset of various neurodegenerative diseases.

This abstract was presented at the 2024 ARVO Imaging in the Eye Conference, held in Seattle, WA, May 4, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×